BridgeBio Pharma Management

Management criteria checks 2/4

BridgeBio Pharma's CEO is Neil Kumar, appointed in Apr 2015, has a tenure of 9.08 years. total yearly compensation is $12.16M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 3.67% of the company’s shares, worth $190.74M. The average tenure of the management team and the board of directors is 5.3 years and 4.3 years respectively.

Key information

Neil Kumar

Chief executive officer

US$12.2m

Total compensation

CEO salary percentage	6.1%
CEO tenure	9.1yrs
CEO ownership	3.7%
Management average tenure	5.3yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

Jan 11

Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Nov 06

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jul 02

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

May 09

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Feb 28

Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts

Jan 09

BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status

Oct 11

Industry Analysts Just Upgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts By 33%

Aug 10

BridgeBio Pharma GAAP EPS of -$0.07 beats by $0.65, revenue of $73.75M beats by $48.75M

Aug 04

BridgeBio, Sentynl's Nulibry get EMA panel nod for approval in EU

Jul 25

BridgeBio Pharma: Yet To Be Proven Business Model

Jun 09

News Flash: Analysts Just Made A Dazzling Upgrade To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Forecasts

May 22

CEO Compensation Analysis

How has Neil Kumar's remuneration changed compared to BridgeBio Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$538m
Dec 31 2023	US$12m	US$742k	-US$643m
Sep 30 2023	n/a	n/a	-US$613m
Jun 30 2023	n/a	n/a	-US$573m
Mar 31 2023	n/a	n/a	-US$425m
Dec 31 2022	US$7m	US$1m	-US$481m
Sep 30 2022	n/a	n/a	-US$491m
Jun 30 2022	n/a	n/a	-US$509m
Mar 31 2022	n/a	n/a	-US$596m
Dec 31 2021	US$26m	US$725k	-US$563m
Sep 30 2021	n/a	n/a	-US$535m
Jun 30 2021	n/a	n/a	-US$495m
Mar 31 2021	n/a	n/a	-US$520m
Dec 31 2020	US$10m	US$550k	-US$449m
Sep 30 2020	n/a	n/a	-US$402m
Jun 30 2020	n/a	n/a	-US$346m
Mar 31 2020	n/a	n/a	-US$291m
Dec 31 2019	US$26m	US$503k	-US$261m
Sep 30 2019	n/a	n/a	-US$226m
Jun 30 2019	n/a	n/a	-US$197m
Mar 31 2019	n/a	n/a	-US$155m
Dec 31 2018	US$450k	US$450k	-US$131m

Compensation vs Market: Neil's total compensation ($USD12.16M) is above average for companies of similar size in the US market ($USD8.43M).

Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.

CEO

Neil Kumar (44 yo)

9.1yrs

Tenure

US$12,158,626

Compensation

Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015.He serves as Pr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Neil Kumar	Co-Founder	9.1yrs	US$12.16m	3.67% $ 190.7m
Charles Homcy	Co-Founder	no data	US$1.11m	0.66% $ 34.1m
Frank McCormick	Co-Founder	no data	US$1.74m	0.59% $ 30.5m
Brian Stephenson	CFO & Secretary	5.6yrs	US$6.65m	0.034% $ 1.7m
Richard Scheller	Chairman of Research & Development	5.3yrs	US$2.01m	no data
Uma Sinha	Chief Scientific Officer	8.1yrs	US$2.75m	no data
Grace Rauh	Vice President of Communications	no data	no data	no data
Eli Wallace	Chief Scientific Officer of Oncology	4.4yrs	no data	no data
Thomas Trimarchi	Chief Product Officer	no data	no data	no data
Eric David	Chief Executive Officer of Gene Therapy	no data	no data	no data
Matthew Outten	Chief Commercial Officer	3yrs	no data	no data
Adora Ndu	Chief Regulatory Affairs Officer	2.3yrs	no data	no data

5.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: BBIO's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Neil Kumar	Co-Founder	9.1yrs	US$12.16m	3.67% $ 190.7m
Charles Homcy	Co-Founder	5.5yrs	US$1.11m	0.66% $ 34.1m
Frank McCormick	Co-Founder	less than a year	US$1.74m	0.59% $ 30.5m
Fred Hassan	Independent Director	2.8yrs	US$600.00k	0.010% $ 535.2k
Ronald Daniels	Independent Director	4.3yrs	US$600.00k	0.0056% $ 288.6k
Eric Aguiar	Independent Director	5.2yrs	US$600.00k	0% $ 0
Randal Scott	Independent Director	3.9yrs	US$600.00k	0.0062% $ 319.2k
Ali Satvat	Independent Director	8.2yrs	US$600.00k	0% $ 0
James Momtazee	Director	8.2yrs	US$600.00k	0.047% $ 2.5m
Jennifer Cook	Director	4.4yrs	US$600.00k	0.0038% $ 198.3k
Wen-Chaun Lo	Independent Director	3.9yrs	US$600.00k	0.14% $ 7.0m
Andrea Ellis	Independent Director	2.8yrs	US$600.00k	0.0064% $ 332.7k

4.3yrs

Average Tenure

61.5yo

Average Age

Experienced Board: BBIO's board of directors are considered experienced (4.3 years average tenure).

BridgeBio Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

Co-Founder exercised options and sold US$1.8m worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

CFO & Secretary exercised options and sold US$632k worth of stock

Recent updates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement

Consensus revenue estimates increase by 83%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

Consensus revenue estimates increase by 44%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 81%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder exercised options and sold US$1.8m worth of stock

New major risk - Financial position

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

Consensus revenue estimates fall by 25%

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

Now 22% undervalued after recent price drop

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Consensus EPS estimates fall by 11%, revenue upgraded

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 13%

BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study

Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy

Price target increased by 20% to US$33.90

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia

CFO & Secretary exercised options and sold US$632k worth of stock

Price target increased by 8.3% to US$28.40

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Co-Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 105%

Price target increased by 8.6% to US$23.90

Consensus revenue estimates decrease by 53%, EPS upgraded

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Key Executive notifies of intention to sell stock

Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021)

Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts

Co-Founder notifies of intention to sell stock

Bridgebio Pharma, Inc. Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

Co-Founder exercised options and sold US$654k worth of stock

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

BridgeBio Pharm and ML Bio Solutions Present 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc Presents Updated Positive Data from Its BBP-812 Canavan Disease Gene Therapy Program At the 51st Annual Meeting of the Child Neurology Society

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen's Lumakras(R) (Sotorasib)

BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status

BridgeBio Pharma, Inc. to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU

BridgeBio Pharma: Down But Not Out

Key Executive exercised options and sold US$102k worth of stock

BridgeBio Pharma, Inc Announces Dosing of First Patient in Phase 1 Trial of BBP-671

BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders

Consensus revenue estimates increase by 33%

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A